Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

T2T.RA_.jpg

Measureable Benefits to Treat-to-Target Management in RA

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen.

Read Article
lupus_0.jpg

Higher Lupus Mortality Among Minority Populations

The February 19th MMWR reports that higher mortality rates in certain patients with systemic lupus erythematosus (SLE); data based on recent San Francisco County statistics showing a four fold higher mortality among Asian and Hispanic/Latina females with SLE.

Read Article
hip.2.jpg

Diagnosis & Treatment of Osteoarthritis Reviewed

Katz, Arant and Loeser have published a comprehensive open-read overview of osteoarthritis (OA) of the hip and knee in JAMA; underscoring the impact, advances, disappointments and guidelines put forth. 

Read Article
ild.jpg

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

Read Article
RheumNow Podcast square

RheumNow Podcast – Systemic Sclerosis Pearls (2.19.2021)

Dr. Jack Cush reviews nearly a dozen news and journal reports from the past 2 weeks on RheumNow.com, including the ACR's new COVID-19 vaccine guidance for patients with rheumatic disease.

Read Article
cancer search news magnify

High Risk Cancer Profiling with Inflammatory Myositis

A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).

Read Article
artangio.jpg (keep)

Avacopan - Is it Really a Win for ANCA-Associated Vasculitis?

The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).

Read Article
alveolar hemorrhage acute

Alveolar Hemorrhage and Mortality in Lupus

Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.

Read Article
T%20cell.jpg

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among pati

Read Article
gout podagra inflammed

MIRROR Study: Pegloticase With Methotrexate in Uncontrolled Gout

Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout. This exploratory, open-label clinical trial screened 17 patients and treated 14 patients (all men, 49.3 ± 8.7 years) with IV pegloticase with MTX (15 mg/week) and folic acid (1 mg/day) 4 weeks prior to and throughout pegloticase treatment.

Read Article
×